Eye tracking devices have established themselves as one of the most effective solutions to ensure independent and fluid communication for patients with ALS and other pathologies that affect speech art...
Read moreLa iniciativa de la URJC 'Un perro, un niño feliz' ha puesto en marcha un programa piloto, que ha demostrado mejoras significativas en el control postural, coordinación oculomotora, comunicación, a...
Read moreAlma Medical has recently signed a collaboration agreement with an award-winning software company, based in Vienna, with the aim of incorporating its algorithms into the new digital health platform: A...
Read moreEl estudio que ha desarrollado el Dr. Pablo Mir junto a su equipo, del grupo de Trastornos del Movimiento del área de Neurociencias del IBiS/HUVR, tenía por objetivo ayudar a definir el perfil del s...
Read moreIt has a budget of 21 million euros and will have a duration of 5 years
Read moreAlma Medical has recently signed a collaboration agreement with an award-winning software company, based in Vienna, with the aim of incorporating its algorithms into the new digital health platform: A...
Read moreParkinson’s is a neurodegenerative disease characterized by the death of dopaminergic neurons. This neuronal death leads to a series of motor manifestations characteristic of the disease, such as tr...
Read moreLas personas que sufren esclerosis lateral amiotrófica (ELA) presentan una composición alterada de las grasas en las células de la médula espinal. Así lo ha confirmado un estudio piloto realiz...
Read moreUn fármaco capaz de inhibir el transporte de serotonina en el sistema nervioso central podría tener efecto para varias enfermedades
Read moreLa edición del genoma mediante editores de bases podría proporcionar soluciones terapéuticas para los pacientes con distrofia muscular de Duchenne, indica un reciente estudio en ratón de la Univer...
Read morehe results of a study carried out by Dr. Mónica Povedano, principal investigator at IDIBELL, reinforce the value of centralized care for the disease
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presented today...
Read more